For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity. Scientific Publication

Feb 15, 2019 | Magazine: Clinical Cancer Research

Ivan Marquez-Rodas, María Angela Aznar, Antonio Calles, Ignacio Melero

Abstract

Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.

CITATION Clin Cancer Res. 2019 Feb 15;25(4):1127-1129. doi: 10.1158/1078-0432.CCR-18-2690. Epub 2018 Sep 27.

see publication in pubmed

Our authors

Imagen del Dr. Ignacio Melero Bermejo, especialista en Inmunología de la Clínica Universidad de Navarra.

Dr. Ignacio Melero Bermejo Curriculum

Senior Researcher | Principal Investigator Immunology and Immunotherapy Research Program